THERAPEUTICSMD INC (TXMD) Stock Price, Quote, News and Overview
NASDAQ:TXMD - Nasdaq - US88338N2062 - Common Stock - Currency: USD
TXMD Quote, Performance and Key Statistics
NASDAQ:TXMD (2/20/2025, 8:00:01 PM)
1.01
-0.01 (-0.98%)
The current stock price of TXMD is 1.01 USD. In the past month the price decreased by -2.88%. In the past year, price decreased by -55.11%.
TXMD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.16 | 828.87B | ||
| JNJ | JOHNSON & JOHNSON | 15.98 | 384.45B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.17 | 371.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.65 | 231.22B | ||
| MRK | MERCK & CO. INC. | 11.48 | 221.80B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.52 | 211.95B | ||
| PFE | PFIZER INC | 8.33 | 146.78B | ||
| SNY | SANOFI-ADR | 13.53 | 135.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.94 | 113.15B | ||
| GSK | GSK PLC-SPON ADR | 7.88 | 75.42B | ||
| ZTS | ZOETIS INC | 26.59 | 71.02B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.5 | 43.94B |
Related stock screener links
About TXMD
Company Profile
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Company Info
THERAPEUTICSMD INC
951 Yamato Road, Suite 220
Boca Raton FLORIDA 33431 US
CEO: Robert G. Finizio
Employees: 1
Company Website: https://www.therapeuticsmd.com/
Investor Relations: http://ir.therapeuticsmd.com/
Phone: 15619611900
THERAPEUTICSMD INC / TXMD FAQ
What is the stock price of THERAPEUTICSMD INC today?
The current stock price of TXMD is 1.01 USD. The price decreased by -0.98% in the last trading session.
What is the ticker symbol for THERAPEUTICSMD INC stock?
The exchange symbol of THERAPEUTICSMD INC is TXMD and it is listed on the Nasdaq exchange.
On which exchange is TXMD stock listed?
TXMD stock is listed on the Nasdaq exchange.
What is THERAPEUTICSMD INC worth?
THERAPEUTICSMD INC (TXMD) has a market capitalization of 11.65M USD. This makes TXMD a Nano Cap stock.
How many employees does THERAPEUTICSMD INC have?
THERAPEUTICSMD INC (TXMD) currently has 1 employees.
What are the support and resistance levels for THERAPEUTICSMD INC (TXMD) stock?
THERAPEUTICSMD INC (TXMD) has a support level at 1 and a resistance level at 1.15. Check the full technical report for a detailed analysis of TXMD support and resistance levels.
Is THERAPEUTICSMD INC (TXMD) expected to grow?
The Revenue of THERAPEUTICSMD INC (TXMD) is expected to grow by 350% in the next year. Check the estimates tab for more information on the TXMD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy THERAPEUTICSMD INC (TXMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TXMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TXMD, evaluating the profitability, health, valuation and growth aspects
- THERAPEUTICSMD INC (TXMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THERAPEUTICSMD INC (TXMD) Sales and EPS estimates to see what analysts future expectations are.
- THERAPEUTICSMD INC (TXMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THERAPEUTICSMD INC (TXMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- THERAPEUTICSMD INC (TXMD) Stock Chart to make your own analysis
- THERAPEUTICSMD INC (TXMD) Latest news and press-releases to stay up to date.
Does THERAPEUTICSMD INC (TXMD) stock pay dividends?
TXMD does not pay a dividend.
When does THERAPEUTICSMD INC (TXMD) report earnings?
THERAPEUTICSMD INC (TXMD) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of THERAPEUTICSMD INC (TXMD)?
THERAPEUTICSMD INC (TXMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
What is the Short Interest ratio of THERAPEUTICSMD INC (TXMD) stock?
The outstanding short interest for THERAPEUTICSMD INC (TXMD) is 1.53% of its float. Check the ownership tab for more information on the TXMD short interest.
TXMD Technical Analysis
TXMD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXMD. TXMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TXMD Financial Highlights
Over the last trailing twelve months TXMD reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -103.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.38% | ||
| ROE | -12.24% | ||
| Debt/Equity | 0 |
TXMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to TXMD. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 192.11% and a revenue growth 350% for TXMD